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INTRODUCTION
One of the most common autoimmune dermatoses with a
chronic relapsing course is psoriasis. Its prevalence in
Europe ranges from 2% to 5% (Christopher et al., 2001; Pa-
risi et al., 2013).
Latvia, together with other Baltic countries, is low-
prevalence psoriasis country, varying from 0.13% to 1.75%
of the total population. There are around 40 000 psoriasis
patients in Latvia, and similar prevalence rates are observed
in Estonia and Lithuania, corresponding to about 35 000
and 76 000 psoriasis patients, respectively (Hartmane et al.,
2016; Global Psoriasis Atlas…). According to literature, the
prevalence of moderate psoriasis, defined by body surface
area (BSA) > 2–10%, varies from 15% to 35.8%, and se-
vere psoriasis, defined by BSA > 10%, from 5% to 12.4%
(Menter et al., 2011; Yeung et al., 2013).
Therapy of patients with moderate-to-severe psoriasis holds
on tree pillars — systemic therapies of non-biological origin
(e.g., methotrexate, cyclosporin, apremilast), phototherapy
and biological therapy (anti-TNF, Il-12/23 inhibitors, Il-17
inhibitors and Il-23 inhibitors). The location of the disease
and the presence of psoriatic arthritis also affect the choice
of therapy. Psoriasis of the hand, foot, or face can be debili-
tating functionally or socially and may deserve a more ag-
gressive treatment approach. Topical treatments, even
though they are cheap, accessible and can be used as ad-
junct treatment for localised lesions, cannot provide
satisfying disease control and fail to meet treatment targets
as monotherapy for moderate-to-severe psoriasis. Attempts
to successfully treat patients with extensive disease require
availability and accessibility of appropriate treatment mo-
dalities, that would not be limited by prescription lines and
would allow to select treatment based on clinical need. Each
of the Baltic countries has a distinct approach to therapy re-
imbursement and different accessibility of treatment, usu-
ally limiting the possibility to tailor treatment according to
patient needs. This article aims to provide an overview of
psoriasis phenotypes, immunopathogenics and treatment in
a restrictive reimbursement environment.
OVERVIEW OF PSORIASIS CLINICAL ASPECTS
Psoriasis can develop at any age and affect not only the
skin, but also other organs and organ systems. Psoriasis is a
multifactorial disease determined by genetic and environ-
mental factors, disorders of keratinocyte proliferation and
differentiation, congenital and adaptive immunity disorders,
as well as a multitude of alterations in the body’s homeosta-
sis. Morphologically it manifests as epidermal cell prolif-
eration, disorders of keratinisation and inflammatory skin
reaction. Clinically it manifests as squamous erythematous
papules and lesions. The most common complications are
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psoriatic arthritis (PsA) and erythroderma (Hartmane et al.,
2016; Rendon et al., 2019).
Psoriasis has a significant impact on the patients' quality of
life. The physical and moral distress it causes is similar to
that in cases of other serious conditions, like oncological,
cardiovascular disease, diabetes, arthritis, and depression
(Möller et al., 2015). There is a high incidence of organ and
systemic co-morbidities in patients with psoriasis, particu-
larly in severe cases: arterial hypertension, hyperlipidaemia,
major adverse cardiovascular events, obesity, diabetes, and
IBD, which often limits the use of CST in the treatment
(Takeshita et al., 2017). Biological therapy should be con-
sidered for use in patients with moderate to severe psoriasis
when conventional systemic therapies and phototherapy are
ineffective or their use is limited due to the patient's poor
quality of life (Dubertret et al., 2006; Mrowietz et al., 2011;
Hartmane et al., 2016). A characteristic feature of psoriasis
vulgaris is an erythematous papule with distinct borders and
silvery scales. These lesions are most seen on the scalp and
extensor surface of elbows and knees. As the papular ele-
ments increase in size and converge, infiltrative foci are
formed, covered with thick scaly crusts (Griffiths et al.,
2007).
The most common phenotypes or clinical subtypes of psori-
asis are psoriasis guttata; psoriasis intertriginosa (or in-
verse psoriasis), psoriasis palmoplantare, and erythroder-
mia psoriatica (Rahman et al., 2005; Griffiths et al., 2007;
Hartmane et al., 2016; Rendon et al., 2019).
Arthritis psoriatica (psoriatic arthritis) is a chronic joint in-
flammation in psoriasis. More often, this form develops
several years after the first manifestations of psoriatic rash,
but in some patients, it is diagnosed before psoriasis. Ac-
cording to the literature, psoriatic arthritis affects 0.35–1%
of the general population and 5–30% of the total number of
patients with psoriasis. The highest incidence occurs be-
tween 45 and 54 years of age, about ten years after the first
skin rash develops (Eder et al., 2016).
Today the leading role of immune-mediated chronic inflam-
mation in the development of psoriasis and psoriatic arthri-
tis has been convincingly demonstrated. These processes
are mediated by the interaction of keratinocytes with cells
of the innate (myeloid and plasmocytic cells, dendritic cells,
macrophages, natural killers) and adaptive immune systems
(T lymphocytes). The course and outcome of the disease de-
pend on the severity of immunological disorder and the
intercellular effects of cytokine regulation (Reich et al.,
2012; Owczarczyk-Saczonek et al., 2018; Christophers et
al., 2019). Immunological disorders in psoriasis are due to
activation of the cellular immune response with the leading
role belonging to T-lymphocytes. T-lymphocytes are classi-
fied according to the secreted factors: 1) Th1 type T-lym-
phocytes, which produce IL-2, INF- and TNF- cytokines
and determine the cell-mediated immune response; 2) and
Th2 type T-lymphocytes, which produce IL-4, IL-5, IL-6,
IL-10, IL-13 and promote humoral immune response. The
pathogenetic line of Th17 CD 4+ T cells was described in
2005 (Rahman et al., 2005; Reich et al., 2005). T lympho-
cytes produce a broad spectrum of cytokines — IL-17A,
IL-17F, IL-6, IL-21, and IL-22, TNF-, as shown in Figure
1. These cells play an important role in protection against
infection and extracellular pathogens that cannot be effec-
tively eliminated with Th1 and Th2 cell types, as well as in
the development of autoimmune diseases and regulation of
anti-tumour immune response (Jain et al., 2009; Martin et
al., 2013; Qu et al., 2013; Chiricozzi et al., 2018).
Recent studies have shown the importance of T regulatory
cells in the development of psoriasis. The primary function
of these cells is to ensure immunological tolerance and to
limit the immune response. In psoriasis, there is a lack of or
dysfunction of T regulatory cells, which, in turn, elicits an
inadequate immune response and is accompanied by a Th1
and Th17 mediated immune response (Hartmane et al.,
2016; Gooderham et al., 2018). Currently, psoriasis is con-
sidered an autoimmune disease based on the activation of
Th1 lymphocytes and hyperproduction of proinflammatory
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Fig. 1. Etiology of psoriasis (from
Chiricozzi et al., 2018).
cytokines TNF-, IFN-, IL-17 and IL-22, as well as due to
the relative decrease in cytokine production by Th2 cells
(Hartmane et al., 2016). Th17 lymphocytes also play a
prominent role in psoriasis: their amount abundantly in-
creases in psoriatic lesions and this increase is accompanied
by the formation of characteristic morphological epidermal
and dermal changes. In the skin, Th17 lymphocytes secrete
proinflammatory cytokines TNF-, IL-17, IL-22, IL-23.
They play a leading role in the pathogenesis of psoriasis and
stimulate neutrophil leukocyte migration and angiogenesis,
shown in Figure 1 (Mattozzi et al., 2013; Boehncke et al.,
2014). An important role in the pathogenesis of psoriasis
and psoriatic arthritis belongs to myeloid dendritic cells,
which are produced in the psoriasis-affected dermis, and in-
creased levels of IL-12 and IL-23. These cytokines promote
the activation of T lymphocytes with subsequent differentia-
tion in Th subpopulations 1 and 17 (Th1 and Th17) with
their characteristic cytokines, including IL-17, which induce
IL-6, IL-8, and other inflammatory proteins in keratinocytes
(Wada et al., 2012; Mattozzi et al., 2013). In addition,
IL-23 has been shown to enhance keratinocyte proliferation
and interfere with differentiation, which in turn leads to epi-
dermal acanthosis and characteristic psoriatic skin lesions.
This cytokine is also important in the development of
psoriatic arthritis (Gooderham et al., 2018).
Psoriasis is a polygenetic disease. The most frequently iden-
tified gene is PSORS1, with a specific locus on chromo-
some 6 (6p21). Various genetic variants associated with
psoriasis have been reported with TNF-, IL-12/23 p40 and
IL-23. Psoriasis is inherited as an autosomal dominant trait
with incomplete penetration. Genetic factors are thought to
cause psoriasis in 60–70% of cases. This is evidenced by
the relatively high incidence of psoriasis among family
members. Genetic markers of the risk of developing psoria-
sis are antigens of the human tissue compatibility antigen
system (HLA). Based on these antigens, two types of psori-
asis are distinguished. The first type (approximately 75% of
patients) has a marked association with HLA antigens Cw6,
A30, B13 or B57, and B-17, cases within family and its first
manifestation in childhood. In such cases, the Koebner phe-
nomenon (positive isomorphic reaction) can often be found.
The second type of psoriasis is characterised by disease on-
set in adulthood, poor association with HLA and family his-
tory, with the Koebner phenomenon rarely being positive.
Type 2 psoriasis is predominantly characterised by a moder-
ate to severe disease course (Rahman et al., 2005; Griffiths
et al., 2007).
The most important step in the pathogenesis of psoriasis is
the imbalance of pro-inflammatory and inflammatory
cytokines. An increased expression IL-1 , IL-6, IL-10,
IL-2, IL-8, IL-12, IL-15, IL-17, IL-22, IL-23, TNF-, IFN-
and IFN- is found in psoriasis. TNF- is one of the most
important cytokines that induces immunopathological re-
sponses in psoriasis. It has many biological effects:
• Increases expression of cell and vascular adhesion mole-
cule-1, which participates in lymphocyte migration to the
area of inflammation.
• Activates lymphocytes and fibroblast proliferation.
• Stimulates the synthesis of leukotrienes, prostaglandins,
and matrix metalloproteinase (especially collagenase),
which induce cartilage and bone destruction.
By activating transcription factors, TNF- regulates the ac-
tivation of genes encoding cytokines IL-1, IFN-, GM-CSF,
IL-6 and proinflammatory chemokine IL-8. During the for-
mation of inflammation, by acting on hepatocytes, TNF-
regulates the immune response by increasing C-reactive
protein. TNF- initiates synthesis of free oxygen radicals
and inhibits apoptosis of inflammatory cells. This cytokine
takes an active role in bone remodelling by enhancing
osteoclastogenesis and possibly promoting intraarticular
osteolysis (a characteristic feature of psoriatic arthritis)
(Rahman et al., 2006; Hartmane et al., 2016).
IL-17 also plays an important role in the development of
immunological inflammation in psoriasis. This cytokine
family includes IL-17A, B, C, D, E, F. Their primary func-
tion is the activation of synthesis of inflammatory cytoki-
nes. The physiological role of IL-17 is to protect the body
from bacterial and fungal infections. In psoriasis, interaction
of IL-17 with its receptors results in induction of the expres-
sion of pro-inflammatory cytokines, chemokines, adhesion
molecules and growth factors, resulting in the progression
of immune inflammation (Gaies et al., 2012). The function
of IL-21 is to maintain Th17 cell balance. This cytokine in-
creases the expression of IL-23 receptors (IL-23R) on T
lymphocytes located in the inflammatory site, promoting
the involvement of new Th17 cells in the pathological pro-
cess.
Psoriatic lesions tend to recur in same areas previously af-
fected by psoriasis, indicating the possible role of immune
memory. This could be explained by the concept of Tissue
Resident memory T cells. The best characterised TRM cells
are CD8+ and express CD103 and CD69 (Watanabe et al.,
2019). These cells are non-recirculating and persist long
term in tissues, providing immediate protection against in-
vading pathogens, and their inappropriate activation might
contribute to the pathogenesis of autoimmune and inflam-
matory disorders. In the skin, apart from psoriasis, these
cells have been described in vitiligo and melanoma (Malik
et al., 2017; Boniface et al., 2018). Resolved psoriatic skin
and disease-naïve non-lesional skin contain populations of
IL-17-producing TRM cells with shared receptor sequences
that recognise common antigens and likely contribute to
disease recurrence after cessation of therapy (Matos et al.,
2017). Looking at Il23/Il-17 axis targeting agents, the most
rapid onset of action is observed with Il-17 inhibitors,
whereas with Il-23 inhibitors onset of action is more grad-
ual, but more sustainable over time, especially in a
bio-experienced population (Reich et al., 2019). After bio-
logical treatment discontinuation, at the cellular and molec-
ular levels, the residual disease activity or so called “scar”
remains. In the future it seems that biological therapy selec-
tion will move from PASI 75, PASI 90, and PASI 100 to
cellular and molecular level efficacy criteria, looking at
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“scar” resolution and healing on the molecular level, which
halts the possibility for psoriasis recurrence (Benezeder et
al., 2019). A similar approach is already adopted in some
clinical trials for Crohn’s disease and ulcerative colitis,
looking beyond the endoscopic healing into histological
mucosal healing and showing positive correlation with deep
remission maintenance (Li et al., 2019; Danese et al.,
2020).
PATHOGENETIC TREATMENT OPTIONS AVAIL-
ABLE TO PSORIASIS PATIENTS IN BALTICS
In psoriasis, IL-23 produced by Th17 lymphocytes inter-
feres with terminal differentiation of keratinocytes, leading
to changes in the epidermis. IL-23 levels correlate with dis-
ease severity (Hao et al., 2014; Gooderham et al., 2018).
Published data indicate the importance of the immune sys-
tem in the development of psoriasis, and therefore treatment
choice should be based on pathogenetic mechanisms (Mon-
teleone et al., 2011). Numerous publications are available
on the use of immunosuppressive agents and methods
(methotrexate, cyclosporine A, UVB phototherapy, PUVA,
etc.) in the treatment of psoriasis. However, these agents do
not provide high clinical efficacy (PASI 90), with unstable
long-term efficacy and common serious side effects (Gaies
et al., 2012). Biological therapeutic agents for the treatment
of psoriasis are increasingly used in Europe and Baltic
countries — treatments that target specific stages of disease
pathogenesis and act by inhibiting specific pro-inflamma-
tory cytokines or immunocompetent cells with specific in-
hibitors (Monteleone et al., 2011; From evolution to revolu-
tion…). In psoriasis, this type of treatment has several
directions: inhibition of abnormal T-cell elimination, T-cell
activation or migration block in tissues; immune correction
to reverse the effects of cytokine activity (raising Th2 cyto-
kine levels to normalise the Th1/Th2 imbalance), and bind-
ing of inflammatory cytokines (Mahil et al., 2016).
With the use of biological drugs in dermatological practice,
there are two treatment stages: initiation and maintenance
phases. The aim of the initiation phase is to determine the
effectiveness and to evaluate possible advantages of contin-
uing the therapy long-term. This phase lasts 12 to 28 weeks.
The goal of maintenance therapy is to provide stable and
long-term remission lasting from a few weeks to a few
years (Mrowietz et al. 2014; Hartmane et al., 2016; Vide et
al., 2017). Primary ineffectiveness due to the patient genetic
characteristics can be overcome by optimising the dose or
regimen (reducing the interval between injections), combin-
ing the biological with low doses of methotrexate or
cyclosporine, and replacing one biological agent with an-
other, preferentially switching the mechanism of action
(Nast et al., 2012; Cather et al., 2014; Kerdel et al., 2015;
Hartmane et al., 2016; Gisondi et al., 2017). Secondary in-
effectiveness or loss of clinical efficacy is also possible,
mainly due to the development of neutralising antibodies
against the drug, which is highly relevant for TNF- inhibi-
tors, especially in the long-term use (Reich et al., 2005;
Reich et al., 2012). The same methods are applied to correct
secondary ineffectiveness as in the case of primary ineffec-
tiveness (Mrowietz et al., 2014; Signorovitch et al., 2015;
Hartmane et al., 2016). When combining a biological drug
with methotrexate or cyclosporin A, it is recommended to
apply a stringent monitoring strategy, according to each par-
ticular drug’s safety and toxicity profile. Safety monitoring
intervals should be shorter in combination therapy. If toxic-
ity is expected to increase, monitoring intervals may be
shortened and additional monitoring parameters may be in-
cluded (Mrowietz et al., 2014; Hartmane et al., 2016).
SITUATION IN THE BALTICS
Latvia, Lithuania, and Estonia operate in a restricted health-
care budget environment with certain similarities between
countries in biologic reimbursement conditions and avail-
ability, as shown in Table 1. Starting from 2018, in all Bal-
tic countries biologic medications are 100% reimbursed by
the state.
Latvia. Biologicals in Latvia are indicated for the treatment
of moderate to severe (severity index PASI  10; damaged
body surface area BSA  10%) chronic psoriasis in patients
for whom another systemic therapy with cyclosporin A,
synthetic retinoids, methotrexate (conventional systemic
therapy, CST) and phototherapy has been ineffective, con-
traindicated or poorly tolerated. In most cases, clinical effi-
cacy of CST and phototherapy is evaluated at 3 to 6 months,
and if no improvement is achieved in this time frame, the
use of biological drugs is considered (Hartmane et al.,
2016). According to data on reimbursed medicines for pso-
riasis diagnosis (ICD10 – L40.0–L40.5; L40.8) from the
Latvian National Health Service in 2019, 11165 unique pa-
tients were treated, with more than 10 000 patients treated
with topical therapy (vitamin D analogues, steroids and ex-
temporal preparations). With regards to psoriatic arthro-
pathies (ICD 10 – M07.0–M07.3), 1060 unique patients
were treated in 2019. These numbers are increasing com-
pared to data from 2017. According to prescription condi-
tions, biologic therapy could be prescribed in Latvia only in
cases when patients have failed to achieve the treatment
goal (loss of response) or have an adverse drug reaction for
CST. In Latvia, 100% reimbursement for patients with pso-
riasis starting from January 2018 is in effect for three bio-
logicals: adalimumab, ustekinumab, and secukinumab
(Medicines to be reimbursed…; Use of public budget re-
sources…). Currently in Latvia, 718 patients are being
treated with conventional systemic therapy (MTX, CSP),
and 113 receive biological therapy, with and increasing
trend as indicated in Table 2 and supported by data for
psoriatic arthritis (Tervishoiuteenuste loetelu….).
Compared with the prevalence data, it seems that not all pa-
tients have access to treatment adequate for their disease se-
verity, and a significant part of patients is not treated at all.
Long-term use of topical steroids in a high proportion of
population is indicative of patients not receiving treatment
according to their disease severity. Treatment with biologi-
cal medicines is prescribed or changed by a decision of a
three-physician dermatovenerologist council at a tertiary
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level outpatient and/or inpatient dermatovenerology service
provider. Treatment could be continued by a dermato-
venerologist at the secondary outpatient dermatovenerology
service provider. Treatment is followed up according to lo-
cal guidelines (Hartmane et al., 2016). Currently, reim-
bursed systemic therapy in Latvia does not fully correspond
to European professional association guidelines with re-
quirement to always start with the cheapest biologic ther-
apy, which in the current situation in anti-TNFs (Nast et al.,
2012). This puts dermatologists in a certain dilemma —
how to achieve the best results with the government-im-
posed therapy sequence. Second line biologic therapy avail-
able is secukinumb and ustekinumab, based on dermato-
venerologist council decision. A similar problem is
observed in other Baltic countries.
Estonia. A dermatovenerologist and pediatrician expert
council can initiate first line biologic therapy for a patient
meeting the following conditions: the disease has lasted for
at least six months and previous treatments have been inef-
fective or intolerable and at least one of the following oc-
curs: alternative standard systemic therapy (acitretin, cyclo-
sporine, methotrexate, bundle UVB and Psoralen + UVA
photochemotherapy) is contraindicated; there is a form of
psoriasis that requires recurrent hospitalisations; there is an
unstable, life-threatening psoriasis form (erythrodermic or
pustular psoriasis) with a PASI score or BSA score > = 10
and DLQI > = 10. In Estonia, 1st line biologic therapy is
anti-TNF (adalimumab or etanercept, available as prescrip-
tion medicines). If there is lack of effect or intolerance to 1st
line biologic therapy, it is possible to proceed to 2nd line
therapy: infliximab, which is covered by hospital service
fee. If there is lack of effect or intolerance to 2nd line bio-
logic therapy, then it is possible to proceed to 3rd line bio-
logic therapy — ustekinumab, secukinumab, guselkumab,
ixekizumab or risankizumab. Treatment with the biological
disease modifying drug is discontinued or replaced by an-
other biological if the patient does not show a 75% im-
provement in the PASI score by week 14 of treatment, com-
pared to pre-treatment, or a 50% improvement in PASI
score or BSA score and a 5% reduction in DLQI points
compared to pre-treatment. Treatment with a biological
medicine should be discontinued in a patient with psoriasis
ineffectiveness if the use of the three active substances has
not achieved the results (Order for the approval …). This
fact highlights new challenges in treating patients who have
failed three biologics, and careful treatment sequence selec-
tion. More data are needed to help in identifying the optimal
treatment sequence for different patient subgroups. In Esto-
nia, 5963 patients are receiving systemic therapy for psoria-
sis, from which 214 are receiving biological therapy (Order
for the approval …).
Lithuania. Treatment with biological medicines is indi-
cated for the treatment of severe psoriasis (PASI > 15) per-
sistent for more than six months, when phototherapy or
standard systemic therapy (MTX or acitretin) has been inef-
fective or contraindicated. Treatment with biological medi-
cines is prescribed, changed, or discontinued (except for
continuity) in the event of remission by a decision of a
three-physician dermatovenerologist council at a tertiary
level outpatient and/or inpatient dermatovenerology service
provider. Treatment with biological medicines is continued
by a dermatovenerologist at the tertiary level outpatient
and/or inpatient dermatovenerology services. The order of
prescribing biological therapy is determined on the basis of
the minimum annual cost of treatment. The 1st line biologic
agent is anti-TNF. Medications other than the 1st line
anti-TNF can be given in certain cases: 1) if the patient
does not tolerate MTX or cannot be co-administered with
infliximab, etanercept, adalimumab, ustekinumab; 2) if the
patient is after tuberculosis treatment, has latent tuberculo-
sis or inactive viral hepatitis, etanercept is given, and if
etanercept is intolerable or ineffective, ustekinumab is
given; 3) if the patient has non-infectious IBD or uveitis,
infliximab or adalimumab should be selected; 4) if the pa-
tient has purulent hydradenitis, adalimumab can be given;
5) if the patient is allergic to one of the anti-TNF, another
anti-TNF or biologic with a different mechanism of action
should be used. The patient is examined by a dermato-
venerologist every 1–3 months. The purpose of the patient's
treatment is remission of the disease or low disease activity.
This goal should be achieved within six months, but if no
improvement is seen after three months, treatment should be
adjusted. The treatment effect is evaluated according to the
dynamics of the following indicators: if the PASI rate im-
proved by  75%, treatment is continued; if the PASI rate
has improved < 50%, treatment is changed; if the PASI rate
has improved by 50–74% and the DLQI is  5, treatment is
continued and; if DLQI > 5, then the treatment is changed
163Proc. Latvian Acad. Sci., Section B, Vol. 75 (2021), No. 3.
Table 2. Dynamics of treated patients in Latvia for the period from 2017 to 2019 for diagnosis psoriasis and psoriatic arthritis
Year Unique patients treated with
reimbursed medicines for diagnosis
Psoriasis (ICD 10 – L40.0-L40.5;
L40.8)
Unique patients treated with
reimbursed medicines for diagnosis
Psoriatic arthritis
(ICD 10 - M07.0-M07.3)
Comment
2017 10 016 882 For PsA medicines were reimbursed by 50 or 100%. For PsO
medicines were reimbursed 50%, 75% or 100%.
2018 10 609 947 For PsO medicines were reimbursed for 75% or 100%, inclusion of
first biological therapy into reimbursement list. PsA reimbursed 100%
2019 11 165 1060 For both PsO and PsA 100% reimbursement
PsO, psoriasis, PsA, psoriatic arthritis (Use of public budget resources…)
(Ministry of Health of the Republic of Lithuania…). In
Lithuania about 1100 patients are receiving systemic ther-
apy and 330 receive biological therapy, and significant pa-
tient pool of about 20 000 uses topical therapy (vitamin D
analogues, topical corticosteroids, as well as extemporal
preparations), indicating overuse of topical steroids in pre-
sumably moderate-to-severe psoriasis (Ministry of Health
of the Republic of Lithuania…).
PERSPECTIVES FOR FUTURE
The Baltic countries lack data on precise prevalence and in-
cidence numbers of psoriasis patients. None of the counties
has government-owned registries comprehensive for psoria-
sis and in Estonia the registry is for biologic therapy pa-
tients. Latvia and Lithuania have a potentially high number
of psoriasis patients not receiving any treatment according
to prevalence data and number of treated patients, and also
relatively low numbers of patients receiving systemic thera-
pies, compared to Estonia. More research is needed to un-
derstand the reasons behind this phenomenon. The low
number of patients receiving biological therapy might be
explained by reluctancy in use of systemic therapies.
Additional challenges in clinical practice are set by reim-
bursement conditions that are changing every three months.
Currently, anti-TNFs are the first line biologic therapy in all
Baltic countries, which require caution in direct implemen-
tation of data from trials into Baltic clinical practice, as in
the majority of cases before initiation of interleukin inhibi-
tors (either Il12/23, Il-17 or Il-23), patients will be
anti-TNF-experienced. The authors therefore suggest pro-
ceeding with a quick switch of therapy if satisfactory treat-
ment results are not achieved within 12–16 therapy weeks
on anti-TNFs and strongly suggest against anti-TNF recy-
cling. Safety switches should be conducted as soon as possi-
ble (Menter et al., 2011; Hartmane et al., 2016). This ap-
proach allows more flexible modification of the therapy and
treatment optimisation for primary non-responders to
anti-TNFs. When choosing second line biologics in the re-
stricted reimbursement environment, several important as-
pects must be considered: efficacy of a biologic drug in a
bio-experienced population, long-term maintenance of re-
sponse, long-term safety data, ease and frequency of admin-
istration, and the immunogenicity profile. Longer drug sur-
vival becomes of utmost importance in limited biologic
therapy availability regions, and additionally protects pa-
tients from exposure to medication with different immuno-
genicity profiles (Nast et al., 2012; Hartmane et al., 2016).
Limitations of this review concern patient number estima-
tions, since these numbers were derived from national au-
thority reported drug consumption data for diagnosis of pso-
riasis, and this may not accurately reflect the patient split
according to disease severity. Additional studies and regis-
tries are needed for psoriasis in Baltics to address this data
gap.
CONCLUSIONS
To our knowledge this is the first article providing a review
of psoriasis forms and pathogenesis with a comprehensive
overview of the reimbursement situation in Baltic countries
for biological therapies and providing previously unpub-
lished data on numbers of treated patients.
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IMUNOPATOGÇNISKAS ÂRSTÇÐANAS IESPÇJAS PSORIÂZES PACIENTIEM IEROBEÞOTAS MADIKAMENTU IEGÂDES
KOMPENSÂCIJAS VIDÇ
Ðî raksta mçríis ir sniegt pârskatu par psoriâzi, pieejamajâm ârstçðanas iespçjâm vidçji smagas lîdz smagas psoriâzes gadîjumos. Sniegti
autoru ieteikumi par daþâdu bioloìisko lîdzekïu lietoðanu pacientiem ar psoriâzi Baltijâ vidç, kur ir ierobeþoti medikamentu iegâdes
kompensâcijas mehânismi.
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